Otsuka Pharmaceutical Acquires Cantargia’s CAN10 Program for Autoimmune Disease Research

Otsuka Pharmaceutical has entered into an agreement to acquire all assets associated with Cantargia’s CAN10 program, a drug candidate currently in early clinical development for the treatment of autoimmune diseases. The deal focuses on the antibody-based therapy, which is being explored as a potential solution for conditions linked to immune system dysfunction.

The CAN10 program represents Cantargia’s efforts to develop innovative treatments targeting autoimmune disorders. The acquisition will transfer ownership of all related assets to Otsuka, enabling the pharmaceutical company to further advance research and development in this area. Details regarding financial terms or timelines for the transaction have not been disclosed.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: July 15, 2025

Related posts:

AI’s Data Analysis Skills Could Expedite Drug Candidate Identification and Optimize Clinical Trials. Pharmacists’ Role Crucial in NSCLC Treatment, Addressing Chemotherapy Dosing and Improving Five-Year Survival Rates FDA to Explore Expedited Approval Process for Rare Disease Treatments Under HHS Initiative Study Finds Individual Differences in Background Sound Detection Influenced by Prior Noise Exposure

Author

Mark Chiang